Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313947 | PMC |
| http://dx.doi.org/10.1136/ard-2022-223529 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study.
Clin Kidney J
October 2024
Department of Nephrology, First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Article Synopsis
- - The study evaluated the safety and effectiveness of telitacicept, a drug targeting B lymphocytes, in treating immunoglobulin A nephropathy (IgAN) in 42 patients, comparing results across three different treatment groups: a whole telitacicept group, a newly treated subgroup, and a conventional immunosuppressive (IS) group.
- - After 24 weeks, both the newly treated telitacicept subgroup and the conventional IS group showed significant reductions in 24-hour proteinuria (a measure of protein in urine), with improvements in the estimated glomerular filtration rate (eGFR), indicating better kidney function.
- - Overall, while all three groups demonstrated improvements, no serious
Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases.
J Autoimmun
September 2024
Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Graduate School of Peking Union Medical College, Nanjing, China; Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Electronic address:
Article Synopsis
- BLyS and APRIL help B cells evade elimination, which can contribute to autoimmune diseases like SLE; targeting these proteins may reduce harmful B cell populations.
- Telitacicept is a fusion protein that inhibits both BLyS and APRIL, disrupting the survival of problematic B cells.
- This review summarizes telitacicept's mechanisms, dosing, efficacy, and safety, highlighting its potential in treating autoimmune diseases based on previous research.
Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review.
Lupus
April 2024
Department of Immunology, Wuhan No. 1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Systemic lupus erythematosus (SLE)-associated hepatitis ("lupus hepatitis") was one of the most frequent causes of liver function abnormalities in patients with SLE. Lupus hepatitis (LH) is commonly treated with conventional treatment, including non-steroidal anti-inflammatory drugs, corticosteroids, and immunomodulators. However, in refractory cases, other treatment options may be required.
View Article and Find Full Text PDFBLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept.
Ann Rheum Dis
June 2023
Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects.
Clin Pharmacol Drug Dev
November 2022
National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China.
Telitacicept, an injectable recombinant human B-lymphocyte stimulating factor receptor-antibody fusion protein, is a new dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. This study evaluates the pharmacokinetic characteristics, tolerability, and safety of a single subcutaneous injection of various doses (80, 160, and 240 mg) of telitacicept in healthy Chinese subjects. This trial is a single-center, randomized, open-label phase I clinical study that includes three dose groups (80, 160, and 240 mg) with 12 subjects in each dose group.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!